1
|
Chuu J, Lu J, Chang H, Chu Y, Peng Y, Ho Y, Shen P, Cheng Y, Cheng C, Liu Y, Wang C. Attenuative effects of collagen peptide from milkfish ( Chanos chanos) scales on ovariectomy-induced osteoporosis. Food Sci Nutr 2024; 12:116-130. [PMID: 38268910 PMCID: PMC10804110 DOI: 10.1002/fsn3.3746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 09/19/2023] [Accepted: 09/21/2023] [Indexed: 01/26/2024] Open
Abstract
Osteoporosis is characterized by low bone mass, bone microarchitecture disruption, and collagen loss, leading to increased fracture risk. In the current study, collagen peptides were extracted from milkfish scales (MS) to develop potential therapeutic candidates for osteoporosis. MS was used to synthesize a crude extract of fish scales (FS), collagen liquid (COL), and hydroxyapatite powder (HA). COL samples were further categorized according to the peptide size of total COL (0.1 mg/mL), COL < 1 kDa (0.1 mg/mL), COL: 1-10 kDa (0.1 mg/mL), and COL > 10 kDa (0.1 mg/mL) to determine it. Semi-quantitative reverse transcription polymerase chain reaction (sqRT-PCR) and immunofluorescence labeling were used to assess the expression levels of specific mRNA and proteins in vitro. For in vivo studies, mice ovariectomy (OVX)-induced postmenopausal osteoporosis were developed, while the sham surgery (Sham) group was treated as a control. Collagen peptides (CP) from MS inhibited osteoclast differentiation in RAW264.7 cells following an insult with nuclear factor kappa-B ligand (RANKL). CP also enhanced osteoblast proliferation in MG-63 cells, possibly through downregulating NFATc1 and TRAP mRNA expression and upregulating ALP and OPG mRNA levels. Furthermore, COL1 kDa also inhibited bone density loss in osteoporotic mice. Taken together, CP may reduce RANKL-induced osteoclast activity while promoting osteoblast synthesis, and therefore may act as a potential therapeutic agent for the prevention and control of osteoporosis.
Collapse
Affiliation(s)
- Jiunn‐Jye Chuu
- Department of Biotechnology and Food TechnologyCollege of Engineering, Southern Taiwan University of ScienceTainanTaiwan
| | - Jeng‐Wei Lu
- Biotech Research and Innovation CentreUniversity of CopenhagenCopenhagenDenmark
- The Finsen LaboratoryRigshospitalet/National University Hospital, Faculty of Health and Medical Sciences, University of CopenhagenCopenhagenDenmark
| | - Hung‐Ju Chang
- Department of Biotechnology and Food TechnologyCollege of Engineering, Southern Taiwan University of ScienceTainanTaiwan
| | - You‐Hsiang Chu
- Department of PathologyTri‐Service General Hospital, National Defense Medical CenterTaipeiTaiwan
| | - Yi‐Jen Peng
- Department of PathologyTri‐Service General Hospital, National Defense Medical CenterTaipeiTaiwan
| | - Yi‐Jung Ho
- Graduate Institute of Life Sciences, National Defense Medical CenterTaipeiTaiwan
- School of Pharmacy, National Defense Medical CenterTaipeiTaiwan
| | - Pei‐Hung Shen
- Department of OrthopedicsTri‐Service General Hospital, National Defense Medical CenterTaipeiTaiwan
| | - Yu‐Shuan Cheng
- Department of Biotechnology and Food TechnologyCollege of Engineering, Southern Taiwan University of ScienceTainanTaiwan
| | - Chia‐Hui Cheng
- Department of Biotechnology and Food TechnologyCollege of Engineering, Southern Taiwan University of ScienceTainanTaiwan
| | - Yi‐Chien Liu
- Department of Biotechnology and Food TechnologyCollege of Engineering, Southern Taiwan University of ScienceTainanTaiwan
| | - Chih‐Chien Wang
- Department of OrthopedicsTri‐Service General Hospital, National Defense Medical CenterTaipeiTaiwan
| |
Collapse
|
2
|
Yves H, Herman J, Uebelhoer M, Wauquier F, Boutin-Wittrant L, Donneau AF, Monseur J, Fotso VM, Duquenne M, Wagner M, Bouvret E, Costes B, Wittrant Y. Oral supplementation with fish cartilage hydrolysate in an adult population suffering from knee pain and function discomfort: results from an innovative approach combining an exploratory clinical study and an ex vivo clinical investigation. BMC Musculoskelet Disord 2023; 24:748. [PMID: 37735385 PMCID: PMC10512646 DOI: 10.1186/s12891-023-06800-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 08/16/2023] [Indexed: 09/23/2023] Open
Abstract
BACKGROUND Aging is frequently associated with impairments of the musculoskeletal system and many elderly people experience joint discomfort or pain which might reduce their ability to move and consequently alter their quality of life. A beneficial effect of fish cartilage hydrolysate (FCH) on pain and joint function has recently been shown in an ACLT/pMMx osteoarthritis rat model. METHODS We therefore performed an exploratory, non-comparative, multi-centric clinical trial including 33 subjects with moderate knee joint discomfort and loss of functionality to investigate the efficacy of FCH on their algo-functional status. We further determined the potential health benefit of FCH in an original clinical ex vivo study investigating the role of FCH human metabolites on primary human chondrocytes. RESULTS FCH significantly improved knee pain and function, as assessed by the Knee injury and Osteoarthritis Outcome Score (KOOS). Moreover, FCH significantly reduced pain at rest and while walking, and patient global assessment (PGA), as assessed by the Visual Analogue Scale (VAS), and improved patients' quality of life (SF-36). FCH metabolites decreased the synthesis of catabolic factors (MMP-13) and pro-inflammatory mediators (NO, PGE2) and limited the inhibitory effect of IL-1β on the synthesis of cartilage matrix components (GAG and collagen). CONCLUSIONS Thus, these data provide insights on the mode of action of FCH in humans and contribute to explain how FCH may relieve pain and improve joint function in subjects with knee discomfort. Although these preliminary data need to be confirmed in a randomized controlled trial, they strongly support the potential health benefit of such an active ingredient. TRIAL REGISTRATION The study was registered on clinicaltrials.gov with the identifier NCT04420091 (09/06/2020).
Collapse
Affiliation(s)
- Henrotin Yves
- Service de Kinésithérapie et de Réadaptation Fonctionnelle, Hôpital Princesse Paola, Vivalia, Rue du Vivier 21, Marche-en-Famenne, 6900, Belgium.
- musculoSKeletal Innovative research Lab (mSKIL), University of Liège, Liège, 4000, Belgium.
| | - Julie Herman
- Artialis SA, Avenue de l'Hôpital 11, Liège, 4000, Belgium
| | | | - Fabien Wauquier
- Clinic'n'Cell SAS, UFR de Médecine et de Pharmacie, 28 Place Henri Dunant, Clermont-Ferrand, TSA, 50400 63001, France
| | - Line Boutin-Wittrant
- Clinic'n'Cell SAS, UFR de Médecine et de Pharmacie, 28 Place Henri Dunant, Clermont-Ferrand, TSA, 50400 63001, France
| | - Anne-Françoise Donneau
- Département des Sciences de la Santé publique, UR BSTAT ULiège, Université de Liège, Avenue Hippocrate 13, Liège, 4000, Belgium
| | - Justine Monseur
- Département des Sciences de la Santé publique, UR BSTAT ULiège, Université de Liège, Avenue Hippocrate 13, Liège, 4000, Belgium
| | | | - Marie Duquenne
- musculoSKeletal Innovative research Lab (mSKIL), University of Liège, Liège, 4000, Belgium
| | - Mélanie Wagner
- Centre Médical Chant d'oiseau, Avenue des Frères Legrain 85, Woluwe-Saint Pierre, 1150, Belgium
| | - Elodie Bouvret
- Abyss Ingredients, 860 Route de Caudan, Caudan, 56850, France
| | | | - Yohann Wittrant
- INRAE, UNH, Clermont-Ferrand, 63001, France
- Université Clermont Auvergne, UFR de Médecine de de Pharmacie, 28 Place Henri Dunant, Clermont-Ferrand, TSA, 50400 63001, France
| |
Collapse
|
3
|
Tossetta G, Fantone S, Licini C, Marzioni D, Mattioli-Belmonte M. The multifaced role of HtrA1 in the development of joint and skeletal disorders. Bone 2022; 157:116350. [PMID: 35131488 DOI: 10.1016/j.bone.2022.116350] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/21/2022] [Accepted: 02/01/2022] [Indexed: 12/15/2022]
Abstract
HtrA1 (High temperature requirement A1) family proteins include four members, widely conserved from prokaryotes to eukaryotes, named HtrA1, HtrA2, HtrA3 and HtrA4. HtrA1 is a serine protease involved in a variety of biological functions regulating many signaling pathways degrading specific components and playing key roles in many human diseases such as neurodegenerative disorders, pregnancy complications and cancer. Due to its role in the breakdown of many ExtraCellular Matrix (ECM) components of articular cartilage such as fibronectin, decorin and aggrecan, HtrA1 encouraged many researches on studying its role in several skeletal diseases (SDs). These studies were further inspired by the fact that HtrA1 is able to regulate the signaling of one of the most important cytokines involved in SDs, the TGFβ-1. This review aims to summarize the data currently available on the role of HtrA1 in skeletal diseases such as Osteoporosis, Rheumatoid Arthritis, Osteoarthritis and Intervertebral Disc Degeneration (IDD). The use of HtrA1 as a marker of frailty in geriatric medicine would represent a powerful tool for identifying older individuals at risk of developing skeletal disorders, evaluating an appropriate intervention to improve quality care in these people avoiding or improving age-related SDs in the elderly population.
Collapse
Affiliation(s)
- Giovanni Tossetta
- Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy; Clinic of Obstetrics and Gynaecology, Department of Clinical Sciences, Università Politecnica delle Marche, Salesi Hospital, Azienda Ospedaliero Universitaria, Ancona, Italy.
| | - Sonia Fantone
- Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy
| | - Caterina Licini
- Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Via Tronto 10/a, Ancona 60126, Italy
| | - Daniela Marzioni
- Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy
| | - Monica Mattioli-Belmonte
- Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Via Tronto 10/a, Ancona 60126, Italy
| |
Collapse
|